隶属于 dartmouth-hitchcock
相关临床试验
485
38 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1983
进行中（未招募）
17
3.5%
已完成
318
65.6%
Enrolling By Invitation
3
0.6%
尚未招募
18
3.7%
招募中
49
10.1%
暂停
1
0.2%
终止
54
11.1%
Unknown
1
0.2%
撤回
24
5.0%
暂无批准数据
- DEA's witness list for the June 29 rescheduling hearing includes Dr. Corey Burchman, who will testify that medical marijuana provides a medical benefit to pain patients based on his clinical experience. - FDA official Dominic Chiapperino will describe the eight-factor analysis supporting the recommendation to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. - Prohibitionist group SAM seeks to subpoena DEA pharmacologist Luli Akinfiresoye, who previously submitted a report linking cannabis to psychosis, depression, and cognitive impairment. - No reform supporters were invited to participate in the hearing, and the DEA judge has denied livestreaming despite acknowledging national public interest in transparency.
- Advanced machine learning algorithms enable liquid biopsies for early lung cancer detection, potentially increasing annual lives saved from 600 to 12,000 in the United States through blood-based screening. - AI-powered imaging systems match radiologists' accuracy in breast cancer detection, demonstrating potential to reduce second reader workload by 88% in UK screening processes. - Deep neural networks in pathology achieve expert-level accuracy in tumor pattern classification, processing slides in under one minute while maintaining diagnostic quality comparable to practicing pathologists.
